Psyence Biomedical (Psyence Biomedical) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Psyence Biomedical's cash to debt ratio for the quarter that ended in Mar. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Psyence Biomedical could pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Psyence Biomedical's Cash-to-Debt or its related term are showing as below:

PBM' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 3 years, Psyence Biomedical's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

PBM's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs PBM: No Debt

Psyence Biomedical Cash-to-Debt Historical Data

The historical data trend for Psyence Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Psyence Biomedical Cash-to-Debt Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Cash-to-Debt

No Debt

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Cash-to-Debt	No Debt	No Debt	No Debt

Competitive Comparison of Psyence Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Psyence Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Cash-to-Debt falls into.

Psyence Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Psyence Biomedical's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Psyence Biomedical had no debt ⁽¹⁾.

Psyence Biomedical's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

Psyence Biomedical had no debt ⁽¹⁾.

Psyence Biomedical (NAS:PBM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Psyence Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024

Psyence Biomedical (Psyence Biomedical) Cash-to-Debt : No Debt (1) (As of Mar. 2023)